India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
'Pollution can have long-term effects on children' Lately, air pollution has been seen high in the major cities of the country including Kathmandu. Even Kathmandu has been included in the list of the most polluted cities in the world. Based on the method of measuring pollution, Kathmandu's air is four times more polluted than normal conditions. This is said based on the amount of 'particulate matter' mixed in the air. The condition of air pollution is determined based on the amount of dust particles i.e. PM 2.5 in the atmosphere. PM 2.5 is fine dust particles in the air with a diameter of 2.5 micrometers, it is a mixed form of solids and chemicals. Since PM 2.5 is very fine, this harmful particle can enter the body and seriously affect the lungs and it may affect health. In this way, what kind of problems can the children's health be caused by the increasing air pollution? What effect does it have on the children of faith? Focusing on these issues, respiratory,...